Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Pre- and post-radical prostatectomy testosterone levels in prostate cancer patients.

Lumbiganon S, Patcharatrakul S, Khongcharoensombat W, Sangkum P.

Int J Impot Res. 2019 Mar;31(2):145-149. doi: 10.1038/s41443-019-0116-0. Epub 2019 Jan 18.

PMID:
30659293
2.

Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.

Dai B, Qu Y, Kong Y, Ye D, Yao X, Zhang S, Wang C, Zhang H, Yang W.

BJU Int. 2012 Dec;110(11 Pt B):E667-72. doi: 10.1111/j.1464-410X.2012.11465.x. Epub 2012 Sep 14.

3.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
4.

Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.

Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, Miles BJ, Lipshultz LI, Khera M.

J Urol. 2013 Aug;190(2):639-44. doi: 10.1016/j.juro.2013.02.002. Epub 2013 Feb 8.

5.

Absence of relationship between steroid hormone levels and prostate cancer tumor grade.

Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK.

Urology. 2009 Feb;73(2):356-61; discussion 361-2. doi: 10.1016/j.urology.2008.07.068. Epub 2008 Nov 26.

PMID:
19036418
6.

Influence of radical prostatectomy on serum hormone levels.

Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC.

J Urol. 1998 Aug;160(2):449-53.

PMID:
9679896
8.

Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.

Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA.

Urology. 2008 Dec;72(6):1240-5. doi: 10.1016/j.urology.2008.06.001. Epub 2008 Aug 9.

PMID:
18692874
9.

A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.

D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schultz D, Kao G, VanArsdalen K, Wein A.

Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):293-302.

PMID:
7928457
10.

Sex hormone-binding globulin is an independent predictor of biochemical recurrence after radical prostatectomy.

Waldert M, Schatzl G, Swietek N, Rom M, Klatte T.

J Urol. 2012 Sep;188(3):792-7. doi: 10.1016/j.juro.2012.05.016. Epub 2012 Jul 19.

PMID:
22818139
11.

Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.

Schnoeller T, Jentzmik F, Rinnab L, Cronauer MV, Damjanoski I, Zengerling F, Ghazal AA, Schrader M, Schrader AJ.

World J Urol. 2013 Apr;31(2):253-9. doi: 10.1007/s00345-012-0902-5. Epub 2012 Jul 5.

PMID:
22763628
12.
13.

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.

Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA.

Urology. 2001 Feb;57(2):281-5.

PMID:
11182337
14.

Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.

Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC.

J Urol. 2009 Aug;182(2):517-25; discussion 525-7. doi: 10.1016/j.juro.2009.04.006. Epub 2009 Jun 13.

PMID:
19524984
15.

Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

Kaufman JM, Graydon RJ.

J Urol. 2004 Sep;172(3):920-2. Review.

PMID:
15310998
16.

Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Zanni G, Suardi N, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2011 Apr;107(8):1243-9. doi: 10.1111/j.1464-410X.2010.09582.x. Epub 2010 Sep 30.

17.

Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?

Lackner JE, Maerk I, Koller A, Bieglmayer C, Marberger M, Kratzik C, Schatzl G.

Urology. 2008 Nov;72(5):1121-4. doi: 10.1016/j.urology.2008.01.066. Epub 2008 Apr 14.

PMID:
18407338
18.

Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.

Neuzillet Y, Raynaud JP, Dreyfus JF, Radulescu C, Rouanne M, Schneider M, Krish S, Rouprêt M, Drouin SJ, Comperat E, Galiano M, Cathelineau X, Validire P, Molinié V, Fiet J, Giton F, Lebret T, Botto H.

Horm Cancer. 2019 Feb;10(1):36-44. doi: 10.1007/s12672-018-0351-8. Epub 2018 Oct 6.

PMID:
30293206
19.

Supplemental Content

Support Center